Usman Baber to Antithrombins
This is a "connection" page, showing publications Usman Baber has written about Antithrombins.
Connection Strength
1.038
-
Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nat Rev Cardiol. 2014 Dec; 11(12):693-703.
Score: 0.471
-
Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin. Thromb Haemost. 2014 Nov; 112(5):1069-70.
Score: 0.116
-
Impact of major bleeding on long-term mortality in anemic versus nonanemic patients undergoing percutaneous coronary intervention using bivalirudin. Am J Cardiol. 2014 May 01; 113(9):1481-6.
Score: 0.112
-
Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. J Thromb Thrombolysis. 2013 May; 35(4):483-93.
Score: 0.106
-
Acute coronary syndromes: Antithrombotics in ACS--moving beyond unfractionated heparin. Nat Rev Cardiol. 2011 Sep 27; 8(11):613-4.
Score: 0.095
-
The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial. Catheter Cardiovasc Interv. 2020 12; 96(7):E688-E694.
Score: 0.042
-
Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1016-1026.
Score: 0.036
-
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. JACC Cardiovasc Interv. 2016 05 23; 9(10):1036-46.
Score: 0.033
-
The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. Catheter Cardiovasc Interv. 2014 Jan 01; 83(1):148-53.
Score: 0.026